I am very pleased to publish this special issue of Investigative and Clinical Urology (Investig Clin Urol, or ICUrology) celebrating our 60th anniversary. In October 2019, ICUrology celebrated its 60th anniversary during the annual meeting of the Korean Urological Association (Fig. 1 ICUrology is an international, peer-reviewed, open access journal published bimonthly. It aims to cover both basic and clinical state-of-the-art research related to the field of urology in the formats of original articles, rapid communications, review articles, special articles, innovations in urology, editorials, and letters to the editor. A total of 8,103 papers were published in Investigative and Clinical Urology from January 1960 to December 2019. A detailed history and publication data are published in the special issue [1] .
For this special issue, we invited 7 worldwide renowned scholars in the field of urology.
The first review is titled "The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer" by Dr. Michael S. Cookson from the University of Oklahoma, USA [2] . The authors emphasized that along with the options available to the clinician for the treatment of men with metastatic castration-sensitive prostate cancer, care of these patients has evolved into a multidisciplinary field with expanding roles for medical, urologic, and radiation oncologists. Dr. Wun-Jae Kim from Chungbuk National University College of Medicine, Korea, reviewed the discovery of urinary biomarkers in urological research [3] . The authors discussed urine-based biomarkers and how these biomarkers can be applied as a diagnostic and prognostic tool in clinical trials and patient care to promote bladder health. In the endourology field, we invited Dr. Daniel D. Eun from Temple University, USA. The authors reviewed the current status of robot-assisted distal ureteral reconstruction for benign pathology [4] . In the field of lower urinary tract dysfunction, Dr. Hann-Chorng Kuo from Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Taiwan, reviewed the clinical application of botulinum toxin A (Botox) in urology, and concluded that although Botox injection is promising for the treatment of overactive bladder and interstitial cystitis/painful bladder syndrome patients refractory to conventional therapies, the need for anesthesia, the occurrence of local complications, and the risks of a large postvoid residual urine volume and urinary tract infection limit its clinical application [5] . In the infection/inflammation field, in a review titled "The human gastrointestinal microbiota and prostate cancer development and treatment" 
